The Health Resources and Services Administration (HRSA) offers the Rural Communities Opioid Response Program-Psychostimulant Support (RCORP-PS) grant. This grant is for expanding prevention, treatment, and recovery services to reduce psychostimulant use disorder morbidity and mortality in high-risk rural communities. Eligible applicants are multi-sectoral consortia (four+ distinct, primarily rural-based entities). The program targets rural individuals, families, and caregivers affected by psychostimulant use, enhancing access. Funding prioritizes historically underserved populations over a three-year performance period.
Opportunity ID: 328944
General Information
Document Type: | Grants Notice |
Funding Opportunity Number: | HRSA-21-091 |
Funding Opportunity Title: | Rural Communities Opioid Response Program-Psychostimulant Support |
Opportunity Category: | Discretionary |
Opportunity Category Explanation: | – |
Funding Instrument Type: | Grant |
Category of Funding Activity: | Health |
Category Explanation: | https://grants.hrsa.gov/2010/Web2External/Interface/FundingCycle/ExternalView.aspx?fCycleID=d2ba6834-022a-48ba-a439-acc66b61ee11 |
Expected Number of Awards: | 15 |
Assistance Listings: | 93.912 — Rural Health Care Services Outreach, Rural Health Network Development and Small Health Care Provider Quality Improvement |
Cost Sharing or Matching Requirement: | No |
Version: | Synopsis 1 |
Posted Date: | Jan 11, 2021 |
Last Updated Date: | Jan 11, 2021 |
Original Closing Date for Applications: | Apr 12, 2021 |
Current Closing Date for Applications: | Apr 12, 2021 |
Archive Date: | Jun 11, 2021 |
Estimated Total Program Funding: | $7,500,000 |
Award Ceiling: | $500,000 |
Award Floor: | $0 |
Eligibility
Eligible Applicants: | Others (see text field entitled “Additional Information on Eligibility” for clarification) |
Additional Information on Eligibility: | Eligible applicants include all domestic public or private, non-profit or for-profit entities, including faith-based and community-based organizations, and federally-recognized tribes and tribal organizations. In addition to the 50 U.S. states, only organizations in the District of Columbia, Guam, the Commonwealth of Puerto Rico, the Northern Mariana Islands, American Samoa, the U.S. Virgin Islands, the Federated State of Micronesia, the Republic of the Marshall Islands, and the Republic of Palau may apply. If you are located outside the 50 states, you must still meet the eligibility requirements. The applicant organization may be located in an urban or rural area and should have the staffing and infrastructure necessary to oversee program activities, serve as the fiscal agent for the award, and ensure that local control for the award is vested in the targeted rural communities. All activities supported by RCORP-PS (i.e., all service delivery sites) must exclusively occur in HRSA-designated rural counties or rural census tracts in urban counties, as defined by the Rural Health Grants Eligibility Analyzer |
Additional Information
Agency Name: | Health Resources and Services Administration |
Description: | The Rural Communities Opioid Response Program (RCORP) is a multi-year initiative by the Health Resources and Services Administration (HRSA) aimed at reducing the morbidity and mortality of substance use disorder (SUD), including opioid use disorder (OUD), in high risk rural communities. This notice announces the opportunity to apply for funding under RCORP-Psychostimulant Support (RCORP-PS). RCORP-PS will advance RCORP’s overall goal by strengthening and expanding prevention, treatment, and recovery services for rural individuals who misuse psychostimulants to enhance their ability to access treatment and move towards recovery. Over the course of a three-year period of performance, RCORP-PS award recipients will implement a set of core psychostimulant use disorder prevention, treatment, and recovery activities, as outlined in Section IV.2. For the purposes of this funding opportunity, psychostimulants include methamphetamine and other illegal drugs, such as cocaine and ecstasy, as well as prescription stimulants for conditions such as attention deficit hyperactivity disorder (ADHD) or depression.1 Applicants should detail in the “Project Abstract” and “Needs Assessment” sections of the Project Narrative which psychostimulants they propose to target with the funding. Given the complex and multifaceted nature of psychostimulant use disorders, as well as the need to secure community buy-in, HRSA requires that applicants be part of broad, multi-sectoral consortia consisting of four or more separately-owned (i.e., different Employment Identification Numbers (EINs)) entities, including the applicant organization.2 A majority, or at least 50 percent, of separately owned consortium members must be physically located in HRSA-designated rural areas, as defined by the Rural Health Grants Eligibility Analyzer. The target population for this award are 1) individuals who are at risk for, have been diagnosed with, and/or are in treatment and/or recovery for psychostimulant use disorders; 2) their families and/or caregivers; and 3) other community members3 who reside in HRSA-designated rural areas. Applicants are encouraged to include populations that have historically suffered from poorer health outcomes, health disparities, and other inequities, as compared to the rest of the target population, when addressing SUD in the proposed service area. For example, a recent study found that more rural racial/ethnic minorities reported their health as fair or poor, that they were unable to see a physician in the past 12 months because of cost, and that they did not have a personal health care provider compared to their non-Hispanic white counterparts.4 Examples of these populations include, but are not limited to, racial and ethnic minorities, people/persons experiencing homelessness, pregnant women, youth and adolescents, etc. The primary focus of this award is psychostimulant misuse and use disorders. However, recognizing that many individuals who misuse psychostimulants are polysubstance users, or have other co-occurring conditions, consortia may also use RCORP-PS funding to help address other SUD-related needs of the target population of individuals, families, and other community members affected by psychostimulant use disorders. Applicants should link any additional activities they propose to the needs of their target population and service area. Please note that no competitive advantage, funding priority, or preference is associated with proposing activities beyond the core/required activities outlined in Section IV.2. Finally, RCORP-PS award recipients are expected to work closely with a HRSA-funded technical assistance (TA) provider throughout the three-year period of performance. Targeted TA will be provided to each award recipient at no additional cost, and is intended to help recipients achieve desired project outcomes, sustain services, align their performance reporting/evaluative activities, implement quality improvement efforts, and overcome challenges to project implementation. HRSA will provide more information about TA support upon receipt of award. |
Link to Additional Information: | – |
Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
Department of Health and Human Services, Health Resources and Services Administration
ruralopioidresponse@hrsa.gov Email:ruralopioidresponse@hrsa.gov |
Version History
Version | Modification Description | Updated Date |
---|---|---|
Related Documents
Folder 328944 Other Supporting Documents-FAQ -> FAQs HRSA-21-091 RCORP-PS_FINAL.pdf
Packages
Agency Contact Information: | Department of Health and Human Services, Health Resources and Services Administration ruralopioidresponse@hrsa.gov Email: ruralopioidresponse@hrsa.gov |
Who Can Apply: | Organization Applicants |
Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
---|---|---|---|---|---|---|
93.912 | HRSA-21-091 | Rural Communities Opioid Response Program-Psychostimulant Support | PKG00264903 | Jan 11, 2021 | Apr 12, 2021 | View |
Package 1
Mandatory forms
328944 SF424_2_1-2.1.pdf
328944 AttachmentForm_1_2-1.2.pdf
328944 PerformanceSite_2_0-2.0.pdf
328944 ProjectNarrativeAttachments_1_2-1.2.pdf
328944 GG_LobbyingForm-1.1.pdf
328944 BudgetNarrativeAttachments_1_2-1.2.pdf
328944 SF424A-1.0.pdf
Optional forms
328944 SFLLL_1_2-1.2.pdf